Five-year data continues to demonstrate effectiveness of Infliximab plus Methotrexate as initial therapy for patient with early Rheumatoid Arthritis
Nieuws van: Leids Universitair Medisch Centrum (LUMC)Five-year follow-up data presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology by Dutch researchers of the Leiden University Medical Center (LUMC) show that patients with active recent-onset rheumatoid arthritis who are treated with intensive monitoring and treatment adjustments aiming at low disease activity, continue to have a good response. Up to 51% achieve remission, and even 10-19% are in drug free remission.
Over the years, patients who received initial treatment with infliximab and methotrexate demonstrated significantly better functional ability than patients in other treatment strategies studied. The study aimed to compare the clinical outcomes of four different treatment strategies in early rheumatoid arthritis patients after five years of disease activity score (DAS) guided therapy.
Lees verder op de website van het LUMC.
www.lumc.nl/0000/13043/13073/80617080319221 - 11 jun 2008
[Beperkt voordeel bij glucoseverlaging]
[Behandeling van hepatitis C vermindert leverfalen en sterfte]